Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 9.88B | 10.03B | 10.01B | 10.12B | 10.17B |
| Total Other Revenue | -39.60M | 599.90M | 1.15B | 1.70B | 2.19B |
| Total Revenue | 9.84B | 9.99B | 9.97B | 10.10B | 10.17B |
| Cost of Revenue | 3.69B | 3.64B | 3.45B | 3.29B | 3.36B |
| Gross Profit | 6.15B | 6.35B | 6.52B | 6.82B | 6.81B |
| SG&A Expenses | 2.50B | 2.53B | 2.34B | 2.38B | 2.41B |
| Depreciation & Amortization | 240.60M | 219.40M | 215.00M | 229.60M | 246.30M |
| Other Operating Expenses | 218.80M | 199.70M | 194.50M | 167.00M | -7.40M |
| Total Operating Expenses | 7.95B | 7.93B | 7.35B | 7.21B | 7.15B |
| Operating Income | 1.88B | 2.07B | 2.62B | 2.89B | 3.02B |
| Income Before Tax | 1.30B | 1.61B | 3.12B | 3.69B | 3.59B |
| Income Tax Expenses | 135.30M | 146.90M | 456.00M | 557.90M | 632.80M |
| Earnings from Continuing Operations | 1.16K | 1.46K | 2.67K | 3.13K | 2.96K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -400.00K | -300.00K | -700.00K | 300.00K | 85.30M |
| Net Income | 1.16B | 1.46B | 2.66B | 3.13B | 3.05B |
| EBIT | 1.88B | 2.07B | 2.62B | 2.89B | 3.02B |
| EBITDA | 2.38B | 2.54B | 3.09B | 3.38B | 3.54B |
| EPS Basic | 8.03 | 10.12 | 18.45 | 21.62 | 20.99 |
| Normalized Basic EPS | 8.03 | 9.19 | 11.32 | 12.01 | 12.72 |
| EPS Diluted | 7.98 | 10.07 | 18.38 | 21.55 | 20.94 |
| Normalized Diluted EPS | 7.99 | 9.14 | 11.26 | 11.96 | 12.67 |
| Average Basic Shares Outstanding | 578.80M | 578.00M | 577.60M | 578.80M | 581.50M |
| Average Diluted Shares Outstanding | 581.20M | 580.70M | 580.70M | 581.40M | 583.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |